Positron-emission-tomography in neurology and psychiatry: Clinical applications;Klinische anwendung der positronenemissions-tomographie in der neurologie und psychiatrie

Nervenheilkunde

Volumn 18, Issue 3, 1999, Pages 132-138

  Bartenstein, P ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Neurology; Positron emission tomography (PET); Psychiatry

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

BRAIN REGION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; EPILEPSY; EXTRAPYRAMIDAL SYNDROME; GLUCOSE METABOLISM; NEUROLOGY; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PSYCHIATRY; RADIODIAGNOSIS; REVIEW;

EID: 0032958755     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Arnold S, Schlaug G, Niemann H, Ebner A, Lüders H, Witte OW, Seitz RJ. Topography of interjetai glucose hypometabolismin unilateral mesiotemporal epilepsy. Neurology 1996; 46: 1422-30.
2. Bartenstein P, Koepp M. Benzodiazepinrezeptordarstellung mit Positronenemissions-Tomographie und Single-Photon-Emissions-Tomographie. Nervenarzt 1995; 66: 412-21.
3. Bartenstein P, Minoshima S, Hirsch C, Buch K et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by single photon emission computed tomography. J Nucl Med 1997; 38: 1095-101.
4. Bartenstein P, Weindl A, Spiegel S, Boecker H, Wenzel R, Ceballos-Baumann A, Minoshima S, Conrad B. Central motor processing in Huntington's disease: a positron emission tomography study. Brain 1997; 120: 1553-67.
5. 99mTc-HMPAO-SPECT. Untersuchungen bei Temporallappenepilepsien mit unilateralem EEG-Fokus. Nervenarzt 1991; 62: 745-9.
6. Brooks DJ. Movement disorders: the clinical issues. Baron JC (ed) Brain dopaminergic systems: Imaging with positron tomography. Amsterdam: Kluwer academic press 1991; 121-34.
7. Chugani HT. Functional brain imaging in pediatrics. Pediatr Clin North Am 1992; 39: 777-99.
8. Davis WK, Mirra SS, Alazraki N. The brain in older persons with and without dementia: findings on MR, PET, and SPECT images. Am J Roentgenol 1994; 162: 1267-78.
9. Di Chiro G, Oldfield E, Wright DC, De Michele D et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Rad 1988; 150: 189-97.
10. Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by f-18 FDG and RB-82 positron emission tomography. J Comput Assist Tomogr 1987; 11: 563-70.
11. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, Römer W, Tatsch K, Weber W, Bartenstein P. F18 FDG-PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med (in press).
12. Engel J Jr. PET scanning in partial epilepsy. Can J Neurol Sci 1991; 18 [Suppl 4]: 588-92.
13. Engel J Jr. Epilepsy surgery. Curr Opin Neurol 1994; 7: 140-7.
14. Engel J Jr., Henry TR, Swartz BE. Positron emission tomography in frontal lobe epilepsy. Adv Neurol 1995; 66: 223-38.
15. Fisher RS, Frost JJ. Epilepsy. J Nucl Med 1991; 32: 651-9.
16. Förstl H. Lehrbuch der Gerontopsychiatrie. Stuttgart: Enke 1997.
17. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Stanus E, Brochti J, Hildebrand J. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography guided stereotactic biopsy. Cancer 1996; 78: 1098-106.
18. Hajek M, Wieser HG, Khan N, Antonini A, Schrott PR, Maguire P, Beer HF, Leenders KL. Preoperative and postoperative glucose consumption in mesiobasal and lateral temporal lobe epilepsy. Neurology 1994; 44: 2125-32.
19. Henry TR, Engel J Jr., Mazziotta JC. Clinical Evaluation of Interictal Fluorine-18-Fluordeoxyglucose PET in partial Epilepsy. J Nucl Med 1993; 34: 1892-8.
20. Herholz K, Pietrzyk U, Voges J, Schröder R, Halber M, Treuer H, Sturm V, Heiss WD. Correlation of glucose consumption and tumor cell density in astrozytomas. A stereotactic PET study. J Neurosurg 1992; 79: 853-8.
21. Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D. Comparability of FDG PET studies in probable Alzheimer's disease. J Nucl Med 1993; 34: 1460-6.
22. Herholz K, Holzer T, Bauer B, Schröder R, Voges J, Ernestus RI, Mendoza G, Weber Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD. C-11 methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50: 1316-22.
23. Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bönner J, Wagner R, Wienhard K, Pawlik G, Heiss WD. Discordant twins with Parkinson's disease: Positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994; 36: 176-82.
24. Jack CR, Petersen RC, Xu YC. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49: 786-94.
25. Jagust WJ. Functional imaging patterns in Alzheimer's disease. Relationship to neurobiology. Ann NY Acad Sci 1996; 777: 22-9.
26. Jobst KA, Hindley NJ, King E, Smith AD. The diagnosis of Alzheimer's disease: a question of image? J Clin Psychiatry 1994; 55 suppl: 22-31.
27. Kamo H, McGeer PL, Harrop R, McGeer EG, Calne DB, Martin WR, Pate BD. Positron emission tomography and histopathology in Pick's disease. Neurology 1987; 37: 439-45.
28. Kuwert T, Lange HW, Boecker H, Titz H, Herzog H, Aulich H, Wang B, Nayak U, Feinendegen LE. Striatal glucose consumption in chorea free subjects at risk of Huntington's disease. J Neurol 1993; 241: 31-6.
29. Kuwert T, Bartenstein P, Grünwald F, Herholz K et al. Klinische Wertigkeit der Positronenemissionstomographie in der Neuromedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz. Nervenarzt 1998; 69: 1045-60.
30. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 1992; 22: 233-46.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimers's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
32. Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, Grassi F, DelSole A, Franceschi M, Giraldi MC. High resolution technetium-99m-HMPAO SPECT inpatients with probable Alzheimer's disease: comparison with fluorine-18-FDG-PET. J Nucl Med 1994; 35: 210-6.
33. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of Fluorine-18-FDG PET. J Nucl Med 1995; 36: 1238-48.
34. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, Ericson L, Johnstrom P. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as a reference. Acta Radiol 1989; 30: 225-32.
35. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with F-dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.
36. Newton MR, Berkovic SF, Austin MC, Rowe CC, McKay WJ, Bladin PF. SPECT in the localisation of extratemporal and temporal seizure foci. J Neurol Neurosurg Psychiatry 1995; 59: 26-30.
37. Noachtar S, Lüders HO, Bromfield EB. Surgical therapy of epilepsy. In: Brandt Th, Caplan C, Dichgans J, Diener J, Kennards C, Neurological Disorders: Course and treatment. San Diego: Academic Press 1996; 183-91.
38. Nordberg A. Functional studies of new drugs for the treatment of Alzheimer's disease. Acta Neurol Scand 1996; suppl 165: 137-44.
39. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H, Murakami M, Uemura K, Yasui N, Mineura K. Clinical value of PET with F-18-Fluorodeoxyglucose and L-methyl-C-11-Methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32: 197-202.
40. Paulus W, Bancher C, Jellinger K. Die Neuropathologie der Demenzen. Dtsch Ärzteblatt 1995; 92: 2340-5.
41. Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, Savoiardo M, Caraceni T, Fazio F. Clinical/metabolic correlations in multiple system atrophy. A fluordeoxyglucose F-18 positron emission tomographic study. Arch Neurol 1995; 52: 179-85.
42. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752-8.
43. Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF, Fenelon G, Geny C, Ricolfi F, Frouin V. Clinical correlates of F-18 fluordopa uptake in five grafted parkinsonian patients. Ann Neurol 1995; 38: 580-8.
44. Ryvlin P, Philippon B, Cinotti L, Froment JC, Le Bars D, Maguire F. Functional neuroimaging strategy in temporal lobe epilepsy: a comparative study of F-18 FDG-PET and Tc-99m HMPAO-SPECT. Ann Neurol 1992; 31: 650-6.
45. Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of I-123 IBZM SPECT and C-11 raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994; 15: 806-13.
46. Spencer SS. The relative contribution of MRI, SPECT and PET imaging in epilepsy. Epilepsia 1994; 35suppl 6; s72-89.
47. 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Comm 1991; 12: 699-707.
48. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with I-123 IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24: 415-21.
49. Villringer K, Jager H, Dichgans M, Ziegler S, Poppinger J, Herz M, Kruschke C, Minoshima S, Pfister HW, Schwaiger M. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995; 19: 532-6.
50. Weber W, Bartenstein P, Gross M, Kinzel D et al. Iodine-123-Alpha-Methyl-L-Tyrosine-SPECT and Fluor-18-Fluorodeoxyglucose-PET in the evaluation of brain tumors. J Nucl Med 1997; 38: 802-8.
51. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, Stöcklin G. Synthesis, Radiopharmacology and first human study of O-(2-F-18Fluoroethyl)-L-Tyrosine (F-18 FET). J Nucl Med 1999; 40: 1-9.